The Europe blood screening market size is expected to
reach USD 1.17 billion by 2025 according to a new report by Grand View
Research, Inc. The market is expected to record a CAGR of 7.7% during the
forecast period. Increasing number of blood transfusion processes performed
along with stringent regulations in Europe mandating screening tests, such as
NAT for testing HIV, HBV, and HCV, is contributing to the market growth.
Moreover, growth in the overall number of
complex surgeries that require a large amount of blood and blood products along
with rising cases of road accidents is expected to drive the market further.
Additionally, import of products through contract agreements and development in
the product technology by manufacturers of blood screening reagents and
instruments are contributing to market expansion in the region.
For example, DiaSystem Scandinavia AB signed a
distribution agreement with SNIBE, an Asian immunology test producer that
focuses on immunoassay analyzers based on CLIA technology. DiaSystem
specializes in the production and supply of reagents used in chemistry and
immunoturbidimetry. This agreement has provided the former company with
automated chemiluminescence instrument delivering a complete analytical system
in areas, such as thyroid, renal function, hepatitis, and hepatic fibrosis.
For full research report on Europe
Blood Screening Market visit here: https://www.grandviewresearch.com/industry-analysis/europe-blood-screening-market
Further key
findings from the study suggest:
- NAT led the technology segment in 2017 owing
to a regulatory obligation for mandatory NAT screening for all blood
donations.
- On the basis of product, reagents led the
Europe blood screening market in 2017
- Germany held a majority of the market share in
2017 due to large number of blood donors.
- Moreover, stringent regulations in the country
for screening of donations also contributed to its growth. The
Paul-Ehrlich-Institut, a medical regulatory body in Germany, mandates NAT
testing for HCV and HIV for all blood donations.
- Roche Diagnostics; Bio-Rad Laboratories, Inc.;
Siemens Healthcare GmbH; Grifols, S.A.; Becton, Dickinson and Company;
Agilent Technologies; Thermo Fisher Scientific, Inc.; and Danaher Corp.
are some of the key companies operating in this market.
Get free request sample of this report
here: https://www.grandviewresearch.com/industry-analysis/europe-blood-screening-market/request/rs1
Grand
View Research has segmented the Europe blood screening market on the basis of
technology, product, and country:
Europe Blood
Screening Technology Outlook (Revenue, USD Million, 2014 - 2025)
- Nucleic Acid
Amplification Test (NAT)
- Enzyme-Linked
Immunosorbent Assay (ELISA)
- Chemiluminescence
Immunoassay (CLIA)
- Next Generation
Sequencing (NGS)
- Western Blotting
Europe Blood
Screening Product Outlook (Revenue, USD Million, 2014 - 2025)
- Reagents
- Instruments
Europe Blood
Screening Country Outlook (Revenue, USD Million, 2014 - 2025)
- U.K.
- Germany
- France
- Italy
- Spain
About Grand View Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
No comments:
Post a Comment